|

Doxorubicin Hydrochloride Clinical Trials

14 actively recruiting trials across 7 locations

No change since July 2026

Also known as: 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, ADRIAMYCIN, HYDROCHLORIDE, ADRIAMYCIN®, Adriacin +22 more

Pipeline

Early 1: 1Phase 1: 1Phase 2: 5Phase 3: 3Phase 2/3: 3

Top Sponsors

  • National Cancer Institute (NCI)4
  • M.D. Anderson Cancer Center4
  • Merck Sharp & Dohme LLC2
  • Children's Oncology Group2
  • Jennifer Crombie, MD1

Indications

  • Cancer14
  • B Lymphoblastic Lymphoma2
  • B Acute Lymphoblastic Leukemia2
  • Chronic Adult T-Cell Leukemia/Lymphoma1
  • Acute Adult T-Cell Leukemia/Lymphoma1

Birmingham, Alabama4 trials

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Children's Hospital of Alabama

Phase 3
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Children's Hospital of Alabama

Phase 2/3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Hospital of Alabama

Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Hospital of Alabama

Phase 3

Houston, Texas4 trials

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M D Anderson Cancer Center

Phase 2
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

M D Anderson Cancer Center

N/A
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

The University of Texas M. D. Anderson Cancer Center

Phase 2

Miami, Florida2 trials

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

University of Miami Sylvester Cancer Center

Phase 2
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

University of Miami Miller School of Medicine

Early 1

Kingman, Arizona1 trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Kingman Regional Medical Center

Phase 2/3

Santa Monica, California1 trial

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

UCLA Hematology/Oncology - Parkside ( Site 0021)

Phase 2

Atlanta, Georgia1 trial

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Emory University Hospital Midtown

Phase 1

Nashville, Tennessee1 trial

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

SCRI Oncology Partners ( Site 7000)

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.